BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
NATO official says members often aren't buying weapons together, and it's a mistake - 26 Fun Urban areas For Seniors To Travel
- 3Blood pressure drug recalled for possible cross-contamination
- 4Building Tough Connections: Individual Bits of knowledge on Association
- 5EU foreign ministers commemorate Russian massacre in Bucha
- McDonald's is bringing two 'KPop Demon Hunters' meals to McDonald's. Here's what they include and when they launch.
- Hilary Duff releases 'Mature,' her 1st song in 10 years
- Indian Health Service is digging out of decades-old construction backlog for medical buildings
- Everything to know about NASA's moon mission launching this week
- Iranian strikes on Israel injure 11 and set chemical plant ablaze
- Humpback whale stranded on Germany's Baltic coast frees itself
- Looking for under-the-radar adventures? Try Norway's Vesterålen
- How mountain terraces have helped Indigenous peoples live with climate uncertainty
- 8 Fundamental Stages: Novice's Manual for Secure Your Android with a VPN
